Arctic Bioscience - Invitation to presentation of half year 2026 results
Arctic Bioscience will publish its financial results for the first half year of 2026 on Thursday 27[th] of August, at 07:00 CET.
The same day at 10:00 CET, the Company will host a webcast to present the results and give an operational update. Following the presentation, it will be opened for questions from the audience.
Webcast details:
Date: Thursday 27[th] of August 2026
Time: 10:00 CET
Format: Webcast and Q&A
Language: Norwegian/English
The presentation can be accessed with the link below:
https://events.teams.microsoft.com/event/6617e53e-29a2-4cf4-ad29
-d999e4d3944d@ce618813-5158-40b5-b6d0
-2f2cd3f39b20?source=copyLinkLegacyShareLinkDialog
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.
For more information, please contact:
Christer L. Valderhaug
CEO
Mobile: +47 920 84 601
E-mail: christer@arctic-bioscience.com
Jone R. Slinning
CFO
Mobile: +47 948 75 469
E-mail: jone@arctic-bioscience.com
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.
The company is developing HRO350 - a novel oral drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.
Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as well as finished goods under the ROMEGA® brand.
Arctic Bioscience is led by a highly skilled team of talents with diverse and highly relevant background.